STUDY DESIGN: Clinical, biochemical, and histologic analysis was performed after in vivo delivery of cDNA encoding various anabolic cytokines and marker genes to the lumbar epidural space of New Zealand white rabbits, using both adenoviral and adeno-associated viral vectors. OBJECTIVE: To mimic errant or misplaced doses of gene therapy to better ascertain the potential risks associated with alternative vectors and transgene products with regard to their application to problems of the intervertebral disc. SUMMARY OF BACKGROUND DATA: Work done with several anabolic cytokines including bone morphogenic proteins and transforming growth factors, has demonstrated the potential of gene therapy. Recently, data has been published demonstrating that improperly dosed or delivered adenoviral-mediated gene therapy within the subarachnoid space can result in significant morbidity in rabbits. There are currently no studies examining the effect of these errors within the epidural space or using an adeno-associated viral (AAV) vector. METHODS: Using either adenoviral or AAV vectors, complementary DNA (cDNA) encoding anabolic cytokines bone morphogenic protein-2 (BMP-2) and transforming growth factor-beta 1 and marker proteins LacZ and green fluorescent protein were injected into the epidural space of 37 New Zealand white rabbits at the L5/6 level. Rabbits were then observed clinically for up to 6 weeks, after which the rabbits were sacrificed in order to perform a comprehensive biochemical and histologic analysis. RESULTS: Following adenoviral-mediated delivery of anabolic cytokine cDNA, up to eighty percent of rabbits demonstrated significant clinical, biochemical, and histologic morbidity. Conversely, AAV-mediated delivery of any cDNA and adenoviral-mediated delivery of marker protein cDNA resulted in no clinical, histologic, or biochemical morbidity. CONCLUSION: Properly dosed and directed gene therapy seems to be both safe and potentially efficacious. This study suggests that side effects of gene therapy may be due to a combination of dosing, transgene product, and vector choice, and that newer AAV vectors may reduce these side-effects and decrease the risk of this technology.
STUDY DESIGN: Clinical, biochemical, and histologic analysis was performed after in vivo delivery of cDNA encoding various anabolic cytokines and marker genes to the lumbar epidural space of New Zealand white rabbits, using both adenoviral and adeno-associated viral vectors. OBJECTIVE: To mimic errant or misplaced doses of gene therapy to better ascertain the potential risks associated with alternative vectors and transgene products with regard to their application to problems of the intervertebral disc. SUMMARY OF BACKGROUND DATA: Work done with several anabolic cytokines including bone morphogenic proteins and transforming growth factors, has demonstrated the potential of gene therapy. Recently, data has been published demonstrating that improperly dosed or delivered adenoviral-mediated gene therapy within the subarachnoid space can result in significant morbidity in rabbits. There are currently no studies examining the effect of these errors within the epidural space or using an adeno-associated viral (AAV) vector. METHODS: Using either adenoviral or AAV vectors, complementary DNA (cDNA) encoding anabolic cytokines bone morphogenic protein-2 (BMP-2) and transforming growth factor-beta 1 and marker proteins LacZ and green fluorescent protein were injected into the epidural space of 37 New Zealand white rabbits at the L5/6 level. Rabbits were then observed clinically for up to 6 weeks, after which the rabbits were sacrificed in order to perform a comprehensive biochemical and histologic analysis. RESULTS: Following adenoviral-mediated delivery of anabolic cytokine cDNA, up to eighty percent of rabbits demonstrated significant clinical, biochemical, and histologic morbidity. Conversely, AAV-mediated delivery of any cDNA and adenoviral-mediated delivery of marker protein cDNA resulted in no clinical, histologic, or biochemical morbidity. CONCLUSION: Properly dosed and directed gene therapy seems to be both safe and potentially efficacious. This study suggests that side effects of gene therapy may be due to a combination of dosing, transgene product, and vector choice, and that newer AAV vectors may reduce these side-effects and decrease the risk of this technology.
Authors: K Nishida; J D Kang; L G Gilbertson; S H Moon; J K Suh; M T Vogt; P D Robbins; C H Evans Journal: Spine (Phila Pa 1976) Date: 1999-12-01 Impact factor: 3.468
Authors: Anne-Kathrin Zaiss; Qiang Liu; Gloria P Bowen; Norman C W Wong; Jeffrey S Bartlett; Daniel A Muruve Journal: J Virol Date: 2002-05 Impact factor: 5.103
Authors: S H Moon; L G Gilbertson; K Nishida; M Knaub; T Muzzonigro; P D Robbins; C H Evans; J D Kang Journal: Spine (Phila Pa 1976) Date: 2000-10-15 Impact factor: 3.468
Authors: Ganjun Feng; Zhanpeng Zhang; Ming Dang; Xiaojin Zhang; Yasmine Doleyres; Yueming Song; Di Chen; Peter X Ma Journal: Biomaterials Date: 2017-03-24 Impact factor: 12.479
Authors: Steven K Leckie; Bernard P Bechara; Robert A Hartman; Gwendolyn A Sowa; Barrett I Woods; Joao P Coelho; William T Witt; Qing D Dong; Brent W Bowman; Kevin M Bell; Nam V Vo; Bing Wang; James D Kang Journal: Spine J Date: 2011-10-22 Impact factor: 4.166
Authors: Justin A Jacobson; Laura Yanoso-Scholl; David G Reynolds; Tulin Dadali; Gino Bradica; Susan Bukata; Edward J Puzas; Michael J Zuscik; Randy Rosier; Regis J O'Keefe; Edward M Schwarz; Hani A Awad Journal: Tissue Eng Part A Date: 2010-10-29 Impact factor: 3.845
Authors: Rachael S Watson-Levings; Glyn D Palmer; Padraic P Levings; E Anthony Dacanay; Christopher H Evans; Steven C Ghivizzani Journal: Front Bioeng Biotechnol Date: 2022-06-28